A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
A legfontosabb adatok
- Ki végzi
- Institute of Hematology & Blood Diseases Hospital, China
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1/2. fázis
- Résztvevők
- 20 fő, tervezett
- Kezdés
- 2025. jan. 15.
- Tervezett befejezés
- 2026. márc. 1.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- nicotinamide adenine dinucleotid/nicotinamide mononucleotide
- A regiszteradat frissítve
- 2025. augusztus 5.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with primary immune thrombocytopenia (ITP), a low platelet count caused by the immune system. Their disease did not respond to, or came back after, steroids and second-line treatment.
- Életkor
- 18 years and above.
- Nem
- Male and female.
- A betegség stádiuma
- ITP diagnosed for at least 3 months. Platelet count below 30 X 10^9/L, measured on at least two days in a row with at least 1 day between tests. ECOG score of 2 or less (able to care for yourself).
- Korábbi kezelés
- No response or relapse after corticosteroids, and after second-line treatment such as TPO/TPORAs, or unable to afford that treatment. One stable maintenance drug is allowed (such as corticosteroids up to 0.5 mg/kg prednisone, or TPO receptor agonists), stable for at least 4 weeks.
- Biomarker vagy leletérték
- Platelet count below 30 X 10^9/L. Women who can become pregnant need a negative pregnancy test.
A részvétel fő kizáró okai
- Low platelets from another cause, such as leukemia, lupus, cirrhosis or drugs.
- Blood clots in the past 12 months, or serious bleeding.
- Rituximab or other CD20 antibodies in the past 3 months, or CD38 antibody that did not work.
- HIV, syphilis, hepatitis B or hepatitis C infection.
- Pregnancy or breastfeeding.
A regiszter feltételei, szó szerint
Mind a 27 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18 and above, male or female
- Conform to the diagnostic criteria of immune Thrombocytopenia (ITP) ≥3 months
- Failure to achieve response or relapse after corticosteroid therapy, and failure to achieve response or relapse after previous second-line treatments such as TPO/TPORAs therapy, or are unable to afford the cost of the treatment
- The platelet count of <30 X 10\^9/L measured within 2 days prior to inclusion (During the screening visit and/or before receiving the study drug, platelet counts must be less than 30×10\^9/L on at least two consecutive occasions, with a minimum interval of 1 day between the two tests.)
- ECOG physical state score ≤ 2 points
- Subjects on stable dose maintenance therapy are allowed to be included (concomitant medications may include corticosteroids (≤0.5 mg/kg of prednisone or equivalent steroids) or TPO receptor agonists, etc.), but at the time of enrollment, only one concomitant medication with a stable dose is permitted. The concomitant medication must have been on a stable dose for at least 4 weeks prior to the first dose of the study drug
- For female patients of childbearing potential, a negative pregnancy test result is required. Both female patients of childbearing potential and male patients must use highly effective contraception during the study and for 4 months/6 months after discontinuing treatment
- Signed and dated written informed consent
Ki nem vehet részt
- Those who are allergic to Nicotinamide adenine dinucleotide or excipients, or who have previously received CD38 monoclonal antibody treatment with no efficacy
- A history of any thrombosis or embolism events within 12 months prior to the first dose, or the presence of extensive and severe bleeding, such as hemoptysis, upper gastrointestinal bleeding, intracranial hemorrhage, sepsis, or other irregular bleeding
- Participation in any other clinical trial involving investigational drugs (including vaccine studies) or exposure to other investigational drugs within 4 weeks or 5 half-lives (whichever is longer) prior to the first dose
- Use of anticoagulants or any drugs with antiplatelet effects (e.g., aspirin) within 2 weeks prior to the first dose
- Receiving azathioprine, danazol, cyclosporine A, tacrolimus, sirolimus, or similar drugs within 4 weeks prior to the first dose; receiving CD20 monoclonal antibodies such as rituximab, cyclophosphamide, vincristine, or similar drugs within 3 months prior to the first dose
- Splenectomy within 6 months prior to the first dose
- Receiving a live vaccine within 4 weeks prior to the first dose, or planning to receive any live vaccine during the study period
- Subjects who have had malignant tumors within the past 5 years prior to screening (excluding completely cured carcinoma in situ of the cervix and non-metastatic squamous cell carcinoma or basal cell carcinoma of the skin)
- Subjects with unresolved toxicity symptoms caused by prior treatments before participating in the trial
- Those with autoimmune hemolytic anemia, or various types of secondary and genetic thrombocytopenia, such as leukemia, lymphoma, multiple myeloma, aplastic anemia, myelodysplastic syndrome, Evans syndrome, common variable immunodeficiency, systemic lupus erythematosus, cirrhosis, antiphospholipid antibody syndrome, pseudo-thrombocytopenia, drug-induced thrombocytopenia (e.g., quinine, heparin, antimicrobial drugs, anticonvulsants, etc.)
- A history of undergoing allogeneic stem cell transplantation or organ transplantation
- A history of clinically significant diseases that, in the investigator's opinion, may pose a risk to the subject's safety or affect the assessment of safety or efficacy during the study if the disease/condition worsens
- Positive for HIV antibodies or syphilis antibodies
- Positive for hepatitis B surface antigen (HBsAg) at screening, or positive for hepatitis B core antibody with a positive HBV-DNA result by polymerase chain reaction (PCR) testing, or positive for hepatitis C virus (HCV) antibodies
- Subjects with mental disorders who are unable to provide informed consent or participate in the trial and follow-up properly
- Any other conditions deemed unsuitable for participation in this study as assessed by the investigator
- Receiving emergency treatment for ITP within 2 weeks prior to the first dose (e.g., methylprednisolone, platelet transfusion, intravenous immunoglobulin, or TPO receptor agonist treatment)
- Exhibiting clinically significant laboratory abnormalities at screening: a) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ the upper limit of normal (ULN); b) Total bilirubin ≥ 1.2 times ULN. ;c) Creatinine or blood urea nitrogen (BUN) ≥ ULN
- Women who are pregnant or breastfeeding, or planning to become pregnant or breastfeed during the study; and men whose partners are planning to become pregnant during the study
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
To evaluate the safety and efficacy of nicotinamide adenine dinucleotide in the treatment of immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including Anti-CD20 Antibody and/or TPO-RA.
A vizsgálat csoportja
- Experimental:A vizsgált kezelés
nicotinamide adenine dinucleotide/nicotinamide mononucleotide
Kezelés: nicotinamide adenine dinucleotid/nicotinamide mononucleotide
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Nicotinamide Adenine Dinucleotide in the Treatment of Primary Immune Thrombocytopenia
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Publikációk
- A regiszteradat frissítve
- 2025. augusztus 5.